Pharmaceutical

Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension

Tabuk obatined rights to commercialise Formosacs l'obetasol propionate ophthalmic suspension 0.05% for inflammation after ocular surgery.

May 11, 2024 - 04:00
Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension
Tabuk obatined rights to commercialise Formosacs l'obetasol propionate ophthalmic suspension 0.05% for inflammation after ocular surgery.
Read the original article

Tags:

Previous Article

Shionogi secures licence for Maze’s Pompe disease treatment

Next Article

Four ways the vaccine rush will define infectious disease trends for CROs in 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Amygdala scores $2m NIAAA grant to develop alcohol use disorder therapy

Amygdala scores $2m NIAAA grant to develop alcohol use ...

Aug 2, 2023

No longer brushed off: A Minnesota clinic tries to rewrite medicine’s approach to miscarriage

No longer brushed off: A Minnesota clinic tries to rewr...

Aug 31, 2023

STAT+: How drug pricing reforms are affecting Bayer’s investments

STAT+: How drug pricing reforms are affecting Bayer’s i...

Jun 20, 2023